External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme
AUTOR(ES)
Bartlett, John M S
FONTE
BMJ Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1995794Documentos Relacionados
- HER2 testing in the UK: consensus from a national consultation
- Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program
- External quality assurance in histopathology: experience of the east of Scotland scheme.
- Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
- HER2 status in breast cancer—an example of pharmacogenetic testing